Latest Champions Biotechnlg (CSBR) Headlines
Post# of 13
Posted On: 03/09/2014 12:10:46 PM
Latest Champions Biotechnlg (CSBR) Headlines
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
PR Newswire - Mon Jan 06, 3:05PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Angela Davies, M.D., as Chief Medical Officer.
Champions Oncology Receives Accreditation From The Joint Commission
GlobeNewswire - Thu Jan 02, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.
Champions Oncology Reports Results for the Quarter Ended October 31, 2013
GlobeNewswire - Thu Dec 12, 3:00PM CST
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended October 31, 2013.
Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial
GlobeNewswire - Tue Dec 10, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.
Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA") certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor.
Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
OtcbbJournal.com Initiates Coverage on ETAH, CSBR, AIVN and MTPR
Marketwire - Tue Sep 03, 7:01AM CDT
Eternity Healthcare, Inc. (OTCQB: ETAH) is a biopharmaceutical company with technologies in drug delivery, specialty pharmaceuticals and medical devices, currently focusing on the development of new subcutaneous formulation of otherwise intramuscular injectable drugs and needle-free injection systems. If you don't like needles, you need to see this report: http://bit.ly/ETAHREPORT
Champions Oncology Announces Two Additions to Senior Management Team
GlobeNewswire - Tue Sep 03, 6:00AM CDT
Champions Oncology (OTC:CSBR) announced today the addition of two members to its senior management team: Dr. Neal Goodwin, previously at Jackson Laboratory ("JAX"), was named Vice President of Corporate Research Development; and Jim McGorry, previously at Genzyme Corporation, was named Executive Vice President and General Manager of the Translational Oncology Solutions business. Both Goodwin and McGorry will be reporting to the CEO of the company.
OTC Daily Alert Stock Watch - Champions Oncology, Inc (OTCQB: CSBR)
WorldStockWire - Thu Aug 15, 10:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Champions Oncology to Host Fourth Quarter and Year-End Results Conference Call on June 10th
GlobeNewswire - Wed Jun 05, 3:00PM CDT
Champions Oncology, Inc. (OTC:CSBR) today announced that it will report its fourth quarter and year-end financial results after market close on Monday, June 10.
Champions Oncology to Exhibit and Present 6 Posters at the 2013 AACR Annual Meeting
GlobeNewswire - Thu Apr 04, 4:56PM CDT
Champions Oncology, Inc. (OTC:CSBR) is pleased to announce that it will be presenting six posters on its Champions TumorGraft(TM) models and Translational Oncology Solutions at the 2013 American Association of Cancer Research (AACR) Annual Meeting being held April 6 - 10 in Washington, DC. Champions will also be exhibiting at the event at Booth #1008.
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
PR Newswire - Mon Jan 06, 3:05PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Angela Davies, M.D., as Chief Medical Officer.
Champions Oncology Receives Accreditation From The Joint Commission
GlobeNewswire - Thu Jan 02, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.
Champions Oncology Reports Results for the Quarter Ended October 31, 2013
GlobeNewswire - Thu Dec 12, 3:00PM CST
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended October 31, 2013.
Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial
GlobeNewswire - Tue Dec 10, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.
Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA") certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor.
Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
OtcbbJournal.com Initiates Coverage on ETAH, CSBR, AIVN and MTPR
Marketwire - Tue Sep 03, 7:01AM CDT
Eternity Healthcare, Inc. (OTCQB: ETAH) is a biopharmaceutical company with technologies in drug delivery, specialty pharmaceuticals and medical devices, currently focusing on the development of new subcutaneous formulation of otherwise intramuscular injectable drugs and needle-free injection systems. If you don't like needles, you need to see this report: http://bit.ly/ETAHREPORT
Champions Oncology Announces Two Additions to Senior Management Team
GlobeNewswire - Tue Sep 03, 6:00AM CDT
Champions Oncology (OTC:CSBR) announced today the addition of two members to its senior management team: Dr. Neal Goodwin, previously at Jackson Laboratory ("JAX"), was named Vice President of Corporate Research Development; and Jim McGorry, previously at Genzyme Corporation, was named Executive Vice President and General Manager of the Translational Oncology Solutions business. Both Goodwin and McGorry will be reporting to the CEO of the company.
OTC Daily Alert Stock Watch - Champions Oncology, Inc (OTCQB: CSBR)
WorldStockWire - Thu Aug 15, 10:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Champions Oncology to Host Fourth Quarter and Year-End Results Conference Call on June 10th
GlobeNewswire - Wed Jun 05, 3:00PM CDT
Champions Oncology, Inc. (OTC:CSBR) today announced that it will report its fourth quarter and year-end financial results after market close on Monday, June 10.
Champions Oncology to Exhibit and Present 6 Posters at the 2013 AACR Annual Meeting
GlobeNewswire - Thu Apr 04, 4:56PM CDT
Champions Oncology, Inc. (OTC:CSBR) is pleased to announce that it will be presenting six posters on its Champions TumorGraft(TM) models and Translational Oncology Solutions at the 2013 American Association of Cancer Research (AACR) Annual Meeting being held April 6 - 10 in Washington, DC. Champions will also be exhibiting at the event at Booth #1008.
(0)
(0)